Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Merli, Francesco  [Clear All Filters]
2014
Bandi T, Affolderbach C, Stefanucci C, Merli F, Skrivervik AK, Mileti G. Compact high-performance continuous-wave double-resonance rubidium standard with 1.4 × 10(-13) τ(-1/2) stability. IEEE Trans Ultrason Ferroelectr Freq Control. 2014;61(11):1769-78.
2016
Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VRuggero, Salvi F, Merli F, Anastasia A, Luminari S, et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016.
2020
Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VRuggero, Zanni M, Merli F, Anastasia A, Luminari S, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136-140.
2022
Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B, Bruna R, Cairoli R, Marchetti M, Romano A, et al. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. Hematol Oncol. 2022.
2023
Thurner L, Ziepert M, Berdel C, Schmidt C, Borchmann P, Kaddu-Mulindwa D, Viardot A, Witzens-Harig M, Dierlamm J, Haenel M, et al. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study. Hemasphere. 2023;7(7):e904.
2024
Stathis A, Pirosa MCristina, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FGaia, Merli F, Guieze R, et al. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica. 2024.